Abstract

Purpose

To compare the survival benefit, pain control and safety of low-power cumulative and traditional high-intensity focused ultrasound (HIFU) for metastatic pancreatic cancer.

Method

We retrospectively analyzed 55 patients with metastatic pancreatic cancer who received HIFU treatment between January 2008 and April 2014 in our department. 23 patients received low-power cumulative HIFU treatment (L group), 32 received the traditional HIFU treatment (T group). Performance status, cancer-related pain and serum biochemistry results were assessed before and after treatment. All patients were followed up until death. The survival rate and adverse events of the two groups were compared.

Results

The baseline characteristics of the two groups were generally well balanced (p > 0.05). The average KPS score after treatment was significantly improved in both groups compared with the baseline score. 36 patients exhibited tumor-related pain at baseline. The pain response rate was significantly higher in the L group (92.3%) than in the T group (52.2%) (p = 0.025). The median overall survival (OS) for the L group was 7.0 months, which was significantly longer than that of the T group (p = 0.000). The 3-month and 6-month survival rates were higher in the L group. The adverse events in both groups included abdominal pain, elevated C-reactive protein (CRP) and elevated amylase. The incidence was lower in the L group than in the T group.

Conclusion

Compared with traditional HIFU treatment, low-power cumulative HIFU treatment showed a significantly higher pain relief rate and survival benefit with a better safety profile in patients with metastatic pancreatic cancer.

中文翻译：

---

新型高强度聚焦超声治疗转移性胰腺癌的疗效

摘要

目的

比较低功率累积和传统高强度聚焦超声（HIFU）对转移性胰腺癌的生存益处，疼痛控制和安全性。

方法

我们回顾性分析了我科在2008年1月至2014年4月之间接受HIFU治疗的55例转移性胰腺癌患者。23例接受低功率HIFU累积治疗（L组），32例接受传统HIFU治疗（T组）。治疗前后评估患者的状态，癌症相关的疼痛和血清生化结果。所有患者均获随访直至死亡。比较两组的生存率和不良反应。

结果

两组的基线特征一般都很好地平衡（p  > 0.05）。与基线得分相比，两组治疗后的平均KPS得分均显着提高。36名患者在基线时表现出与肿瘤相关的疼痛。L组的疼痛缓解率（92.3％）显着高于T组（52.2％）（p  = 0.025）。L组的中位总生存期（OS）为7.0个月，明显长于T组（p  = 0.000）。L组的3个月和6个月生存率较高。两组的不良事件均包括腹痛，C反应蛋白（CRP）升高和淀粉酶升高。L组的发生率低于T组。

结论

与传统的HIFU治疗相比，低功率累积HIFU治疗对转移性胰腺癌患者显示出明显更高的止痛率和生存获益，并具有更好的安全性。